TREA

Eye therapy system

Follow

Information

  • Patent Grant
  • 8870934
  • Patent Number
    8,870,934
  • Date Filed
    Tuesday, September 24, 2013
    10 years ago
  • Date Issued
    Tuesday, October 28, 2014
    9 years ago
Information
Abstract
Embodiments apply a cross-linking agent to a region of corneal tissue. The cross-linking agent improves the ability of the corneal tissue to resist undesired structural changes. For example, the cross-linking agent may be Riboflavin or Rose Bengal, and the initiating element may be photoactivating light, such as ultraviolet (UV) light. In these embodiments, the photoactivating light initiates cross-linking activity by irradiating the applied cross-linking agent to release reactive oxygen radicals in the corneal tissue. The cross-linking agent acts as a sensitizer to convert O2 into singlet oxygen which causes cross-linking within the corneal tissue. The rate of cross-linking in the cornea is related to the concentration of O2 present when the cross-linking agent is irradiated with photoactivating light. Accordingly, the embodiments control the concentration of O2 during irradiation to increase or decrease the rate of cross-linking and achieve a desired amount of cross-linking.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The invention pertains to the field of conducting eye therapy, and more particularly, to systems and methods for stabilizing changes to corneal tissue as a part of eye therapy.


2. Description of Related Art


A variety of eye disorders, such as myopia, keratoconus, and hyperopia, involve abnormal shaping of the cornea. Laser-assisted in-situ keratomileusis (LASIK) is one of a number of corrective procedures that reshape the cornea so that light traveling through the cornea is properly focused onto the retina located in the back of the eye. During LASIK eye surgery, an instrument called a microkeratome is used to cut a thin flap in the cornea. The corneal flap is then peeled back and the underlying corneal tissue is ablated to the desired shape with an excimer laser. After the desired reshaping of the cornea is achieved, the corneal flap is put back in place and the surgery is complete.


In another corrective procedure that reshapes the cornea, thermokeratoplasty provides a noninvasive procedure that applies electrical energy in the microwave or radio frequency (RF) band to the cornea. In particular, the electrical energy raises the corneal temperature until the collagen fibers in the cornea shrink at about 60° C. The onset of shrinkage is rapid, and stresses resulting from this shrinkage reshape the corneal surface. Thus, application of energy according to particular patterns, including, but not limited to, circular or annular patterns, causes aspects of the cornea to flatten and improves vision in the eye.


The success of procedures, such as LASIK or thermokeratoplasty, in addressing eye disorders, such as myopia, keratoconus, and hyperopia, depends on whether the desired reshaping of the cornea has been sufficiently stabilized.


SUMMARY OF THE INVENTION

Embodiments according to aspects of the present invention provide systems and methods for stabilizing corneal tissue and improving its biomechanical strength. For example, the embodiments may be employed to preserve the desired reshaping of corneal tissue produced by eye therapies, such as thermokeratoplasty or LASIK surgery.


In particular, the embodiments apply a cross-linking agent to a region of corneal tissue. The cross-linking agent improves the ability of the corneal tissue to resist undesired structural changes. For example, the cross-linking agent may be Riboflavin or Rose Bengal, and the initiating element may be photoactivating light, such as ultraviolet (UV) light. In these embodiments, the photoactivating light initiates cross-linking activity by irradiating the applied cross-linking agent to release reactive oxygen radicals in the corneal tissue. The cross-linking agent, e.g. Riboflavin or Rose Bengal, acts as a sensitizer to convert O2 into singlet oxygen which causes cross-linking within the corneal tissue.


The rate of cross-linking in the cornea is related to the concentration of O2 present when the cross-linking agent is irradiated with photoactivating light. Accordingly, aspects of the present invention control the concentration of O2 during irradiation to increase or decrease the rate of cross-linking and achieve a desired amount of cross-linking.


To increase the presence of O2 during irradiation, the cross-linking agent in some embodiments may be saturated or supersaturated with O2 before application to the cornea.


In other embodiments, a steady state of O2 may be maintained above the eye to expose the cornea to higher concentrations of O2 during irradiation.


In further embodiments, a gel, such as a methylcellulose gel, may be saturated or supersaturated with O2. The gel acts as a carrier for O2. The gel may then be applied to the cornea after the cross-linking agent has been applied to the cornea. Alternatively, the gel may be mixed with the cross-linking agent before the cross-linking agent is applied to the cornea.


In some embodiments, the rate of cross-linking may be monitored in real time and the concentration of O2 may be dynamically increased or decreased to achieve a desired amount of cross-linking. Thus, embodiments include a system that provides a first amount of O2 above the eye to introduce O2 to the corneal tissue and expose the cornea to a first concentration of O2 during irradiation. Based on the feedback from the real time monitoring, the system can then provide a second amount of O2 above the eye to introduce another amount of O2 to the corneal tissue and expose the cornea to a second concentration of O2 during irradiation. The first amount of O2 may be greater than the second amount of O2, or vice versa. Changing the cornea's exposure from the first concentration to the second concentration changes the rate of cross-linking in the corneal tissue. Further changes to the concentration of O2 during irradiation may be effected to control the rate of cross-linking. When necessary, the amount of O2 above the eye may be substantially reduced to zero to prevent further introduction of O2 to the corneal tissue during irradiation.


Other aspects, features, and advantages of the present invention are readily apparent from the following detailed description, by illustrating a number of exemplary embodiments and implementations, including the best mode contemplated for carrying out the present invention. The present invention is also capable of other and different embodiments, and its several details can be modified in various respects, all without departing from the spirit and scope of the present invention. Accordingly, the drawings and descriptions are to be regarded as illustrative in nature, and not as restrictive. The invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A illustrates a high resolution image of a cornea after energy has been applied.



FIG. 1B illustrates another high resolution images of the cornea of FIG. 1A.



FIG. 1C illustrates a histology image of the cornea of FIG. 1A.



FIG. 1D illustrates another histology image of the cornea of FIG. 1A.



FIG. 2A illustrates an example approach for stabilizing or strengthening corneal tissue by applying a cross-linking agent according to aspects of the present invention.



FIG. 2B illustrates an example approach for stabilizing or strengthening corneal tissue by applying Riboflavin as a cross-linking agent according to aspects of the present invention.



FIG. 3A illustrates an example device that may be employed to supersaturate a cross-linking agent with O2 according to aspects of the present invention.



FIG. 3B illustrates an example approach for stabilizing or strengthening corneal tissue by applying supersaturated Riboflavin as a cross-linking agent according to aspects of the present invention.



FIG. 4A illustrates an example device that may be employed to supersaturate a carrier gel with O2 according to aspects of the present invention.



FIG. 4B illustrates an example approach for stabilizing or strengthening corneal tissue by mixing Riboflavin with a gel supersaturated with O2 according to aspects of the present invention.



FIG. 4C illustrates an example approach for stabilizing or strengthening corneal tissue by applying a gel supersaturated with O2 according to aspects of the present invention.



FIG. 5A illustrates an example device that may be employed maintain a steady state of O2 above the eye to expose the cornea to higher concentrations of O2 according to aspects of the present invention.



FIG. 5B illustrates another example device that may be employed to maintain a steady state of O2 above the eye to expose the cornea to higher concentrations of O2 according to aspects of the present invention.



FIG. 5C illustrates an example approach for stabilizing or strengthening corneal tissue by applying a state of O2 above the eye to expose the cornea to higher concentrations of O2.



FIG. 6 illustrates an example approach for stabilizing or strengthening corneal tissue by monitoring cross-linking activity in real time and controlling the amount of O2 exposure to achieve desired rates of cross-linking according to aspects of the present invention.



FIG. 7 illustrates an increase in Young's modulus as a function of age and is associated with cross-linking.





DETAILED DESCRIPTION

Embodiments according to aspects of the present invention provide systems and methods for stabilizing corneal tissue and improving its biomechanical strength. For example, the embodiments may be employed to preserve the desired reshaping of corneal tissue produced by eye therapies, such as thermokeratoplasty or LASIK surgery.



FIGS. 1A-D illustrate an example of the effect of applying heat to corneal tissue with thermokeratoplasty. In particular, FIGS. 1A and 1B illustrate high resolution images of cornea 2 after heat has been applied. As FIGS. 1A and 1B show, a lesion 4 extends from the corneal surface 2A to a mid-depth region 2B in the corneal stroma 2C. The lesion 4 is the result of changes in corneal structure induced by the application of heat as described above. These changes in structure result in an overall reshaping of the cornea 2. It is noted that the application of heat, however, has not resulted in any heat-related damage to the corneal tissue.


As further illustrated in FIGS. 1A and 1B, the changes in corneal structure are localized and limited to an area and a depth specifically determined by the controlled application of heat. FIGS. 1C and 1D illustrate histology images in which the tissue shown in FIGS. 1A and 1B has been stained to highlight the structural changes induced by the heat. In particular, the difference between the structure of collagen fibrils in the mid-depth region 2B where heat has penetrated and the structure of collagen fibrils outside the region 2B is clearly visible. Thus, the collagen fibrils outside the region 2B remain generally unaffected by the application of heat, while the collagen fibrils inside the region 2B have been rearranged and formed new bonds to create completely different structures. In other words, unlike processes, such as orthokeratology, which compress areas of the cornea to reshape the cornea via mechanical deformation, the collagen fibrils in the region 2B are in an entirely new state. Treatment of the cornea produces structural changes to the stroma 2C, and the optomechanical properties of the cornea change under stress. Such changes include: straightening out the waviness of the collagen fibrils; slippage and rotation of individual lamellae; and breakdown of aggregated molecular superstructures into smaller units.


Although treatments, such thermokeratoplasty, may initially achieve desired reshaping of the cornea, the desired effects of reshaping the cornea may be mitigated or reversed at least partially if the collagen fibrils continue to change after the desired reshaping has been achieved. Therefore, aspects of the present invention provide approaches for preserving the desired corneal structure and shape that result from an eye therapy, such as thermokeratoplasty. In general, embodiments provide approaches for initiating molecular cross-linking of the corneal collagen to stabilize the corneal tissue and improve its biomechanical strength.


Referring to FIG. 2A, a treatment, such as thermokeratoplasty or LASIK surgery, is applied in step 210 to generate structural changes in the cornea and produce a desired shape change. In step 220, the corneal tissue is treated with a cross-linking agent 222. The cross-linking agent may be applied directly on the treated tissue and/or in areas around the treated tissue. In some embodiments, the cross-linking agent may be an ophthalmic solution that is broadly delivered by a dropper, syringe, or the like. Alternatively, the cross-linking agent may be selectively applied as an ophthalmic ointment with an appropriate ointment applicator. The cross-linking agent 222 is then activated in step 230 with an initiating element 232. Activation of the cross-linking agent 222, for example, may be triggered thermally by the application of microwaves or light from a corresponding energy or light source. The resulting cross-linking between collagen fibrils provides resistance to changes in corneal structure.


As described previously with reference to FIGS. 1A-D, for example, the lesion 4 extends from the corneal surface 2A to a mid-depth region 2B in the corneal stroma 2C. In such cases, the application of the cross-linking agent in step 220 introduces sufficient amounts of cross-linking agent to mid-depth regions of the corneal tissue where stronger and more stable structure is desired.


As FIG. 2B shows further, Ribloflavin is applied as a cross-linking agent 222′ to the corneal tissue in step 220. In addition, light from a ultraviolet (UV) light source may be applied as an initiating element 232′ in step 230 to initiate cross-linking in the corneal areas treated with Ribloflavin. Specifically, the UV light initiates cross-linking activity by causing the applied Riboflavin to release reactive oxygen radicals in the corneal tissue. The Riboflavin acts as a sensitizer to convert O2 into singlet oxygen which causes cross-linking within the corneal tissue.


In human tissue, O2 content is very low compared to the atmosphere. The rate of cross-linking in the cornea, however, is related to the concentration of O2 when it is irradiated with photoactivating light. Therefore, it may be advantageous to increase or decrease the concentration of O2 actively during irradiation to control the rate of cross-linking until a desired amount of cross-linking is achieved.


An approach according to aspects of the present invention involves supersaturating the Riboflavin with O2. Thus, when the Riboflavin is applied to the eye, a higher concentration of O2 is delivered directly into the cornea with the Riboflavin and affects the conversion of O2 into singlet oxygen when the Riboflavin is exposed to the photoactivating light. As illustrated in FIG. 3A, the Riboflavin 222′ may be stored in a closed vessel, e.g., a vial, 300 under increased O2 pressure 305. The increased O2 pressure 305 results in a higher equilibrium concentration of O2 in the Riboflavin 222′. The walls 310 of the vessel 300 are preferably opaque or otherwise prevent visible, UV, or other light from entering the vessel interior 301 to minimize the degradation of the Riboflavin 222′. Accordingly, referring to FIG. 3B, the step 215 supersaturates the Riboflavin 222′ with O2 so that a supersaturated Riboflavin 222′ is applied in step 220.


According to other aspects of the present invention, rather than supersaturating the Riboflavin 222′ with O2, another substance, such as a gel (e.g., a methylcellulose gel), may be saturated or supersaturated with O2. As illustrated in FIG. 4A, a gel 421 may be stored in an interior 401 of a closed vessel, e.g., a vial, 400 under increased O2 pressure 405. The increased O2 pressure 405 results in a higher equilibrium concentration of O2 in the gel 421. The gel can then act as a carrier for O2.


Referring to FIG. 4B, step 216 saturates a gel 421 with O2, and step 217 mixes the supersaturated gel 421 with the Riboflavin 222′, so that a mixture 422 containing the Riboflavin 222′ and the supersaturated gel 421 is applied in step 220. Alternatively, referring to FIG. 4C, step 216 saturates a gel 421 with O2, and step 225 applies the gel 421 to the cornea after the Riboflavin 222′ has been applied to the cornea. In both FIGS. 4A and 4B, the gel 421 increases the presence of O2 when the Riboflavin 222′ is activated with the UV light.


According to additional aspects of the present invention, a steady state of O2 may be maintained at the surface of the cornea to expose the cornea to a selected amount of O2 and cause O2 to enter the cornea. The photoactivating light can then be applied to a cornea with the desired O2 content.


As shown in FIG. 5A, a ring 500 is placed on the eye 1 to supply O2 to the cornea 2 during irradiation. The ring 500 includes one or more ports 502 that direct a steady flow of O2 to the cornea 2, which has been treated by Riboflavin. The flow applies O2 at high pressure against the cornea 2, so that more O2 is available during the irradiation of the Riboflavin in the corneal tissue. The ring 500 may optionally be held in place by suction.


As FIG. 5B illustrates, in another embodiment, an enclosure 510 receiving a supply of O2 through a port 512 is placed on the eye to establish a steady state of O2. The enclosure 510 may be held in place by a suction ring 512. As shown in FIG. 5B, the enclosure 510 may be a cup-like structure. The enclosure 510 maintains the O2 at a higher pressure, e.g., higher than ambient, against the surface of the cornea 2. The concentration of O2 within the enclosure 510 and above the surface of the cornea 2 can approach 100%. The O2 within the enclosure 510 makes more O2 to be available for the irradiation of the Riboflavin in the corneal tissue. At least a portion of the walls 514 of the enclosure 510 may be translucent to allow photoactivating light to pass through the enclosure 510 to irradiate the cornea 2 and activate the Riboflavin applied to the cornea 2. Alternatively, the light source may be disposed within the enclosure. The enclosure 510 may also include a valve that allows the gas to be released.


Accordingly, referring to FIG. 5C, step 227 establishes a steady state of O2 above the corneal surface before the photoactivating light 232′ is applied in step 230 to initiate cross-linking with the Riboflavin 222′.


Referring to FIG. 6, the rate of cross-linking may be monitored in real time and the concentration of O2 may be dynamically increased or decreased to achieve a desired amount of cross-linking. As FIG. 6 illustrates, corneal tissue is treated with Riboflavin 222′ in step 220. In step 228, a first amount of O2 is provided above the corneal surface to introduce O2 to the corneal tissue and establish a first concentration of O2 in the cornea during irradiation. The devices described with reference to FIGS. 5A and 5B may be employed to change the amount of O2 is provided above the corneal surface. The Riboflavin 222′ is then activated in step 230 with UV light 232′.


In step 240, the amount of cross-linking resulting from the activation of the Riboflavin 222′ is monitored. One technique for monitoring the cross-linking employs polarimetry to measure corneal birefringence and to determine the structure of the corneal tissue. In particular, the technique measures the effects of cross-linking on corneal structure by applying polarized light to the corneal tissue. Birefringence is the decomposition of a light beam into two beams when it passes through materials that have anisotropic (directionally dependent) structure. The corneal stroma is anisotropic and its index of refractions depends on direction. The cornea behaves like a curved biaxial crystal with the fast axis orthogonal to the corneal surface and the slow axis (or corneal polarization axis) tangential to the corneal surface. Accordingly, a light beam emerging from the living eye after a double pass through the ocular optics contains information on the polarization properties of the ocular structures (except optically inactive humours). FIG. 7 illustrates the increase in Young's modulus with age and is associated with cross-linking. Referring to TABLE 1, it has been shown that the stiffening effects of applying Riboflavin and UV light to initiate cross-linking appears to be equivalent to the effect of aging to the cornea by more than 500 years. Referring to TABLE 2, a study has also shown that the amount of depolarized light emerging from the eye generally correlates with the age of the subjects in the study. Bueno, J. M. J. Op. A: Pure Appl. Opt. 6 (2004), S91-S99. Thus, the degree of polarization may provide a measure of cross-linking.













TABLE 1







Condition
Young's Modulus
Age (Years)




















Normal
0.49
80



UV Riboflavin
2.25
600



Glutaraldehyde
3.76
1000



















TABLE 2





Subject
Age
Degree of Polarization

















1
24
0.92


2
27
0.76


3
30
0.80


4
32
0.77


5
41
0.74


6
67
0.61


7
70
0.67









The technique of using birefringence to monitor the structural changes resulting from cross-linking is described further in U.S. Provisional Patent Application No. 61/388,963, filed Oct. 1, 2010, the contents of which are entirely incorporated herein by reference. A controller, employing conventional computer hardware or similar processing hardware, can be used to monitor the amount of cross-linking. Such hardware may operate by reading and executing programmed instructions that are stored or fixed on computer-readable media, such as conventional computer disk. In addition to being coupled to monitoring hardware, the controller may be coupled to, and automatically control, the device(s) that provide the O2 above the corneal surface.


Based on the information from the real time monitoring in step 240, step 250 provides a second amount of O2 above the eye to introduce another amount of O2 to the corneal tissue and expose the cornea to a second concentration of O2 during irradiation with UV light 232′ in step 260. Steps 240, 250, and 260 may be repeated any number of times to change the concentration of O2 during irradiation to control the rate of cross-linking dynamically.


The first amount of O2 in step 228 may be greater than the second amount of O2 in step 250, or vice versa. Changing the cornea's exposure from the first concentration to the second concentration changes the rate of cross-linking in the corneal tissue as desired. If the information from step 240 indicates that the first amount of O2 is too low, step 250 provides a second amount of O2 that is greater than the first amount of O2. On the other hand, if the information from step 240 indicates that the first amount of O2 is too high, step 250 provides a second amount of O2 that is greater than the first amount of O2. It may be necessary to remove the first amount of O2, e.g., from the enclosure 510, before providing the second amount of O2 in step 250.


In some cases, it may be desired to provide substantially zero O2 in step 250 to minimize or reduce the amount of O2 in the corneal tissue during irradiation in step 260. Accordingly, step 250 may introduce a non-O2 element or substance above the corneal surface. For example, nitrogen gas (N2) may replace the O2 supplied by the devices 500 and 510 shown in FIGS. 5A and 5B.


Although the embodiments described above may employ Riboflavin as a cross-linking agent, it is understood that other substances may be employed as a cross-linking agent. Thus, an embodiment may employ Rose Bengal (4,5,6,7-tetrachloro-2′,4′,5′,7′-tetraiodofluorescein) as a cross-linking agent (similar to the embodiment of FIG. 3B). Rose Bengal has been approved for application to the eye as a stain to identify damage to conjunctival and corneal cells. However, Rose Bengal can also initiate cross-linking activity within corneal collagen to stabilize the corneal tissue and improve its biomechanical strength. Like Riboflavin, photoactivating light 332′ may be applied to initiate cross-linking activity by causing the Rose Bengal to convert O2 in the corneal tissue into singlet oxygen. The photoactivating light 332′ may include, for example, UV light or green light.


Thus, with Rose Bengal, the rate of cross-linking in the cornea is related to the concentration of O2 when it is irradiated with photoactivating light. Therefore, it may be advantageous to increase or decrease the concentration of O2 during irradiation to control the rate of cross-linking and achieve the desired cross-linking. The concentration of O2 may be increased or decreased according to the techniques described previously. For example, the Rose Bengal may be saturated or supersaturated with O2 before application to the cornea. Additionally or alternatively, a steady state of O2 may be maintained above the eye to expose the cornea to higher concentrations of O2 and cause O2 to enter the cornea. In general, the O2 content in the cornea may be controlled for more effective cross-linking for any agent that operates to produce a reactive oxygen species for cross-linking.


Although aspects of the present invention have been described in connection with thermokeratoplasty or LASIK surgery, it is understood that the systems and methods described may be applied in other contexts. In other words, it may be advantageous to stabilize corneal structure with a cross-linking agent as described above as a part of any treatment.


While the invention is susceptible to various modifications and alternative forms, specific embodiments and methods thereof have been shown by way of example in the drawings and are described in detail herein. It should be understood, however, that it is not intended to limit the invention to the particular forms or methods disclosed, but, to the contrary, the intention is to cover all modifications, equivalents and alternatives falling within the spirit and scope of the invention.

Claims
  • 1. A system for controlling cross-linking in corneal tissue, comprising: a cross-linking system configured to apply a cross-linking agent to a cornea and activate the applied cross-linking agent to cause cross-linking in corneal fibrils of the cornea;a monitoring system configured to determine an amount of cross-linking in the cornea; anda delivery device configured to provide a gas mixture at a surface of the cornea, the gas mixture determining an O2 content for activation of the cross-linking agent in the cornea, the delivery device being configured to selectively increase or decrease the O2 content provided at the surface of the cornea to control the rate of cross-linking in response to the amount of cross-linking in the cornea determined by the monitoring system.
  • 2. The system according to claim 1, wherein the monitoring device includes a controller.
  • 3. The system according to claim 1, further comprising a cross-linking-agent source storing the cross-linking agent, the cross-linking agent being Riboflavin or Rose Bengal.
  • 4. The system according to claim 1, wherein the delivery device includes a ring that includes one or more ports that direct the gas mixture at the cornea.
  • 5. The system according to claim 1, wherein the delivery device includes an enclosure that is pressurized with the gas mixture against the surface of the cornea.
  • 6. The system according to claim 5, wherein the gas mixture within the enclosure establishes a steady state of O2 above the surface of the cornea.
  • 7. The system according to claim 5, wherein the enclosure includes one or more walls, at least a portion of the one or more walls being configured to allow microwave energy or photoactivating light generated by the cross-linking system to pass through the enclosure to activate the cross-linking agent.
  • 8. The system according to claim 5, wherein the cross-linking system includes an activator that provides microwave energy or photoactivating light to the cornea, the activator being disposed within the enclosure.
  • 9. The system according to claim 1, wherein the cross-linking system includes an activator configured to provide microwave energy to the cornea that activates the cross-linking agent.
  • 10. The system according to claim 1, wherein the cross-linking system includes a light source configured to provide photoactivating light to the cornea that activates the cross-linking agent.
  • 11. The system according to claim 1, wherein the monitoring system employs polarimetry to measure corneal birefringence and to determine the amount of cross-linking in the cornea in real time.
  • 12. The system according to claim 1, wherein the delivery device initially provides a first gas mixture that determines a first O2 content in the cornea and, in response to the amount of cross-linking determined by the monitoring system, provides a second gas mixture that determines a second O2 content in the cornea, the first gas mixture and the second gas mixture providing different amounts of O2, the delivery device providing dynamic control of cross-linking in the cornea.
  • 13. The system according to claim 12, wherein the delivery device is configured such that one of the first and second gas mixtures consists of one or more non-O2 gases.
  • 14. The system according to claim 1, wherein the monitoring system is configured to determine the stiffness of the corneal tissue.
  • 15. The system according to claim 14, wherein the monitoring system is configure to determine the stiffness of the corneal tissue by employing polarimetry to measure a corneal birefringence.
  • 16. A system for controlling cross-linking in corneal tissue, comprising: a vessel that stores a cross-linking agent under O2 pressure higher than ambient pressure that increases the equilibrium concentration of O2 for the cross-linking agent causing the cross-linking agent to be saturated or supersaturated with O2; anda cross-linking system configured to apply the cross-linking agent to corneal fibrils in the corneal tissue, the saturation or supersaturation of the cross-linking agent increasing the O2 content in the corneal tissue when the cross-linking agent is applied, the cross-linking system being further configured to activate the applied cross-linking agent, the activated cross-linking agent causing cross-linking in the corneal fibrils.
  • 17. The system according to claim 16, further comprising a cross-linking-agent source storing the cross-linking agent, wherein the cross-linking agent is Riboflavin or Rose Bengal.
  • 18. The system according to claim 16, wherein the cross-linking system includes an activator configured to activate the cross-linking agent with microwave energy or photactivating light.
  • 19. A system for controlling cross-linking in corneal tissue, comprising: an applicator configured to apply a cross-linking agent to a cornea;an activator configured to activate the cross-linking agent causing cross-linking in corneal fibrils of the cornea;a delivery device configured to provide a gas mixture at a surface of the cornea, the gas mixture determining an O2 content for activation of the cross-linking agent in the cornea, the delivery device being configured to selectively increase or decrease the O2 content provided at the surface of the cornea to control the rate of cross-linking.
  • 20. The system according to claim 19, wherein the delivery device includes an enclosure that is pressurized with the gas mixture against the surface of the cornea.
  • 21. The system according to claim 19, wherein the activator is configured to provide microwave energy to the cornea that activates the cross-linking agent.
  • 22. The system according to claim 19, wherein the activator is configured to provide photoactivating light to the cornea that activates the cross-linking agent.
  • 23. The system according to claim 19, wherein the applicator includes a syringe.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/909,228, filed Oct. 21, 2010, now allowed, which claims priority to U.S. Provisional Application No. 61/253,736, filed Oct. 21, 2009, the contents of these applications being incorporated entirely herein by reference.

US Referenced Citations (157)
Number Name Date Kind
4034750 Seiderman Jul 1977 A
4161013 Grodzinsky et al. Jul 1979 A
4326529 Doss et al. Apr 1982 A
4381007 Doss Apr 1983 A
4712543 Baron Dec 1987 A
4764007 Task Aug 1988 A
4805616 Pao Feb 1989 A
4881543 Trembly et al. Nov 1989 A
4891043 Zeimer et al. Jan 1990 A
4994058 Raven et al. Feb 1991 A
5016615 Driller et al. May 1991 A
5019074 Muller May 1991 A
5103005 Gyure et al. Apr 1992 A
5171254 Sher Dec 1992 A
5281211 Parel et al. Jan 1994 A
5332802 Kelman et al. Jul 1994 A
5461212 Seiler et al. Oct 1995 A
5490849 Smith Feb 1996 A
5512966 Snook Apr 1996 A
5618284 Sand Apr 1997 A
5624437 Freeman et al. Apr 1997 A
5634921 Hood et al. Jun 1997 A
5766171 Silvestrini Jun 1998 A
5779696 Berry et al. Jul 1998 A
5814040 Nelson et al. Sep 1998 A
5885275 Muller Mar 1999 A
5891131 Rajan et al. Apr 1999 A
5910110 Bastable Jun 1999 A
6033396 Huang et al. Mar 2000 A
6099521 Shadduck Aug 2000 A
6101411 Newsome Aug 2000 A
6104959 Spertell Aug 2000 A
6139876 Kolta Oct 2000 A
6161544 DeVore et al. Dec 2000 A
6162210 Shadduck Dec 2000 A
6218360 Cintron et al. Apr 2001 B1
6223075 Beck et al. Apr 2001 B1
6280436 Freeman et al. Aug 2001 B1
6293938 Muller et al. Sep 2001 B1
6319273 Chen et al. Nov 2001 B1
6325792 Swinger et al. Dec 2001 B1
6334074 Spertell Dec 2001 B1
6342053 Berry Jan 2002 B1
6394999 Williams et al. May 2002 B1
6402739 Neev Jun 2002 B1
6413255 Stern Jul 2002 B1
6478792 Hansel Nov 2002 B1
6520956 Huang Feb 2003 B1
6520958 Shimmick et al. Feb 2003 B1
6537545 Karageozian et al. Mar 2003 B1
6572849 Shahinian, Jr. Jun 2003 B2
6617963 Watters et al. Sep 2003 B1
6918904 Peyman Jul 2005 B1
6946440 DeWoolfson et al. Sep 2005 B1
7044945 Sand May 2006 B2
7073510 Redmond et al. Jul 2006 B2
7130835 Cox et al. Oct 2006 B2
7141049 Stern et al. Nov 2006 B2
7192429 Trembly Mar 2007 B2
7270658 Woloszko et al. Sep 2007 B2
7331350 Kochevar et al. Feb 2008 B2
7402562 DeWoolfson et al. Jul 2008 B2
7753943 Strong Jul 2010 B2
8115919 Yun et al. Feb 2012 B2
8366689 Marshall et al. Feb 2013 B2
8414911 Mattson et al. Apr 2013 B2
20010041856 McDaniel Nov 2001 A1
20020002369 Hood Jan 2002 A1
20020013577 Frey et al. Jan 2002 A1
20020049437 Silvestrini Apr 2002 A1
20020099363 Woodward et al. Jul 2002 A1
20020164379 Nishihara et al. Nov 2002 A1
20030018255 Martin et al. Jan 2003 A1
20030175259 Karageozian et al. Sep 2003 A1
20030216728 Stern et al. Nov 2003 A1
20040001821 Silver et al. Jan 2004 A1
20040002694 Pawlowski et al. Jan 2004 A1
20040071778 Bellmann et al. Apr 2004 A1
20040093046 Sand May 2004 A1
20040111086 Trembly et al. Jun 2004 A1
20040143250 Trembly Jul 2004 A1
20040199079 Chuck et al. Oct 2004 A1
20040199158 Hood et al. Oct 2004 A1
20040204707 Hood et al. Oct 2004 A1
20040243160 Shiuey et al. Dec 2004 A1
20050038471 Chan et al. Feb 2005 A1
20050149006 Peyman Jul 2005 A1
20050271590 Schwartz et al. Dec 2005 A1
20060135957 Panescu Jun 2006 A1
20060149343 Altshuler et al. Jul 2006 A1
20060177430 Bhushan et al. Aug 2006 A1
20060189964 Anderson et al. Aug 2006 A1
20060276777 Coroneo Dec 2006 A1
20060287662 Berry et al. Dec 2006 A1
20070048340 Ferren et al. Mar 2007 A1
20070055227 Khalaj et al. Mar 2007 A1
20070074722 Giroux et al. Apr 2007 A1
20070099966 Fabricant May 2007 A1
20070123845 Lubatschowski May 2007 A1
20070135805 Peyman Jun 2007 A1
20070142828 Peyman Jun 2007 A1
20070161976 Trembly Jul 2007 A1
20070203547 Costello et al. Aug 2007 A1
20070244470 Barker et al. Oct 2007 A1
20070244496 Hellenkamp Oct 2007 A1
20070265603 Pinelli Nov 2007 A1
20080009901 Redmond et al. Jan 2008 A1
20080015660 Herekar Jan 2008 A1
20080027328 Klopotek et al. Jan 2008 A1
20080063627 Stucke et al. Mar 2008 A1
20080114283 Mattson et al. May 2008 A1
20080139671 Herekar Jun 2008 A1
20080208177 Mrochen et al. Aug 2008 A1
20090024117 Muller Jan 2009 A1
20090054879 Berry Feb 2009 A1
20090069798 Muller et al. Mar 2009 A1
20090130176 Bossy-Nobs et al. May 2009 A1
20090149842 Muller et al. Jun 2009 A1
20090149923 Herekar Jun 2009 A1
20090171305 El Hage Jul 2009 A1
20090192437 Soltz et al. Jul 2009 A1
20090209954 Muller et al. Aug 2009 A1
20090234335 Yee Sep 2009 A1
20090275929 Zickler Nov 2009 A1
20090276042 Hughes et al. Nov 2009 A1
20100028407 Del Priore et al. Feb 2010 A1
20100036488 De Juan, Jr. et al. Feb 2010 A1
20100057060 Herekar Mar 2010 A1
20100069894 Mrochen et al. Mar 2010 A1
20100082018 Panthakey et al. Apr 2010 A1
20100094197 Marshall et al. Apr 2010 A1
20100114109 Peyman May 2010 A1
20100149842 Muller et al. Jun 2010 A1
20100173019 Paik et al. Jul 2010 A1
20100189817 Krueger et al. Jul 2010 A1
20100204584 Ornberg et al. Aug 2010 A1
20100210996 Peyman Aug 2010 A1
20100286156 Pinelli Nov 2010 A1
20100318017 Lewis et al. Dec 2010 A1
20110077624 Brady et al. Mar 2011 A1
20110098790 Daxer Apr 2011 A1
20110118654 Muller et al. May 2011 A1
20110152219 Stagni et al. Jun 2011 A1
20110190742 Anisimov Aug 2011 A1
20110208300 de Juan, Jr. et al. Aug 2011 A1
20110237999 Muller et al. Sep 2011 A1
20110264082 Mrochen et al. Oct 2011 A1
20110288466 Muller et al. Nov 2011 A1
20110301524 Bueler et al. Dec 2011 A1
20120083772 Rubinfield et al. Apr 2012 A1
20120215155 Muller et al. Aug 2012 A1
20120283621 Muller et al. Nov 2012 A1
20120289886 Muller et al. Nov 2012 A1
20120303008 Muller et al. Nov 2012 A1
20120310083 Friedman et al. Dec 2012 A1
20130060187 Friedman et al. Mar 2013 A1
20130085370 Friedman et al. Apr 2013 A1
Foreign Referenced Citations (33)
Number Date Country
10 2008 046834 Mar 2010 DE
1 561 440 Aug 2005 EP
1 790 383 May 2007 EP
2 253 321 Nov 2010 EP
MI2010A001236 May 2010 IT
2086215 Aug 1997 RU
2098057 Dec 1997 RU
2121825 Nov 1998 RU
2127099 Mar 1999 RU
2127100 Mar 1999 RU
2309713 Nov 2007 RU
2359716 Jun 2009 RU
2420330 Jun 2011 RU
2428152 Sep 2011 RU
2456971 Jul 2012 RU
WO 0074648 Dec 2000 WO
WO 2004052223 Jun 2004 WO
WO 2005110397 Nov 2005 WO
WO 2006012947 Feb 2006 WO
WO 2006128038 Nov 2006 WO
WO 2007001926 Jan 2007 WO
WO 2007120457 Oct 2007 WO
WO 2007143111 Dec 2007 WO
WO 2008000478 Jan 2008 WO
WO 2009073213 Jun 2009 WO
WO 2009146151 Dec 2009 WO
WO 2010011119 Jan 2010 WO
WO 2010023705 Mar 2010 WO
WO 2010093908 Aug 2010 WO
WO 2011019940 Feb 2011 WO
WO 2011116306 Sep 2011 WO
WO 2012004726 Jan 2012 WO
WO 2012047307 Apr 2013 WO
Non-Patent Literature Citations (83)
Entry
Marzouky, et. al., Tensioactive-mediated Transepithelial Corneal Cross-linking—First Laboratory Report, European Ophthalmic Review, 2009, 3(2), pp. 67-70.
Thorton, I. et. al., “Biomechancial Effects of Intraocular Pressure Elevation on Optic Berve/Lamina Cribrosa before and after Peripapillary Scleral Collagen Cross-Linking.” Invest. Ophthalm,ol. Vis. Sci., Mar. 2009, 50(3): pp. 1227-1233.
Zhang, Y. et al., “Effect of the Synthetic NC-1059 Peptide on Diffusion of Riboflavin Across an Intact Corneal Epithelium”, May 6, 2012, ARBO 2012 Annual Meeting Abstract, 140 Stroma and Keratocytes, program number: 1073, poster board No. A109 (1 page).
International Search Report and Written Opinion mailed Feb. 6, 2014 which issued in International Patent Application No. PCT/US2013/068588 (6 pages).
Koller, T. et. Al., “Complication and failure rates after corneal crosslinking,”Journal Cataract and refractive surgery, vol. 35, No. 8, Aug. 2009, pp. 1358-1362.
Acosta a. et al., “Corneal Stroma Regeneration in Felines After Supradescemetic Keratoprothesis Implantation,” Cornea, vol. 25, No. 7, pp. 830-838; Aug. 2006 (9 pages).
Baier J. et al., “Singlet Oxygen Generation by UVA Light Exposure of Endogenous Photosensitizers,” Biophysical Journal, vol. 91(4), pp. 1452-1459; Aug. 15, 2006 (8 pages).
Ballou, D. et al., “Direct Demonstration Of Superoxide Anion Production During The Oxidation Of Reduced Flavin And Of Its Catalytic Decomposition By Erythrocuprein,” Biochemical and Biophysical Research Communications vol. 36, No. 6, pp. 898-904, Jul. 11, 1969 (7 pages).
Berjano E., et al., “Radio-Frequency Heating of the Cornea: Theoretical Model and In Vitro Experiments,” IEEE Transactions on Biomedical Engineering, vol. 49, No. 3, pp. 196-205; Mar. 2002 (10 pages).
Berjano E., et al., “Ring Electrode for Radio-frequency Heating of the Cornea: Modelling and in vitro Experiments,” Medical & Biological Engineering & Computing, vol. 41, pp. 630-639; Jun. 2003 (10 pages).
Brüel, A., “Changes In Biomechanical Properties, Composition Of Collagen And Elastin, And Advanced Glycation Endproducts Of The Rat Aorta In Relation To Age,” Atherosclerosis 127, Mar. 14, 1996 (11 pages).
Chai, D. et al., “Quantitative Assessment of UVA—Riboflavin Corneal Cross-Linking Using Nonlinear Optical Microscopy,” Investigative Ophthalmology & Visual Science, Jun. 2011, vol. 52, No. 7, 4231-4238 (8 pages).
Chan B.P., et al., “Effects of photochemical crosslinking on the microstructure of collagen and a feasibility study on controlled protein release;” Acta Biomaterialia, vol. 4, Issue 6, pp. 1627-1636; Jul. 1, 2008 (10 pages).
Chandonnet, “CO2 Laser Annular Thermokeratoplasty: A Preliminary Study,” Lasers in Surgery and Medicine, vol. 12, pp. 264-273; 1992 (10 pages).
Clinical Trials.gov, “Riboflavin Mediated Corneal Crosslinking for Stabilizing Progression of Keratoconus (CCL),” University Hospital Freiburg, Feb. 20, 2008; retrieved from http://www.clinicaltrials.gov/ct2/show/NCT00626717, on Apr. 26, 2011 (3 pages).
Corbett M., et al., “Effect of Collagenase Inhibitors on Corneal Haze after PRK,” Exp. Eye Res., vol. 72, Issue 3, pp. 253-259; Jan. 2001 (7 pages).
Coskenseven E. et al., “Comparative Study of Corneal Collagen Cross-linking With Riboflaving and UVA Irradiation in Patients With Keratoconus,” Journal of Refractive Surgery, vol. 25, issue 4, pp. 371-376; Apr. 2009 (6 pages).
“Definity (perflutren) injection, suspension [Bristol-Myers Squibb Medical Imaging],” http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8338, revised Sep. 2008, retrieved via the internet archive from http://web.archive.org/web/20100321105500/http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8338, on Dec. 14, 2011 (15 pages).
Ehlers W., et al., “Factors Affecting Therapeutic Concentration of Topical Aminocaproic Acid in Traumatic Hyphema,” Investigative Ophthalmology & Visual Science, vol. 31, No. 11, pp. 2389-2394; Nov. 1990 (6 pp.).
Erskine H., “Avedro Becomes Sponsor of US FDA Clinical Trials of Corneal Collagen Crosslinking,” Press Release, Mar. 16, 2010 (1 page).
Fite et al. Noninvasive Multimodal Evaluation of Bioengineered Cartilage Constructs Combining Time-Resolved Fluorescence and Ultrasound Imaging. Tissue Eng: Part C vol. 17, No. 4, 2011 (10 pages).
Frucht-Pery, et al. “Iontophoresis—gentamicin delivery into the rabbit cornea, using a hydrogel delivery probe, ” Jun. 20, 2003 (5 pages).
Gibson, Q. et al., “The Oxidation Of Reduced Flavin Mononucleotide By Molecular Oxygen,” Biochem. J. (1962) 83, 368-377 (10 pages).
Givens et al. “A Photoactivated Diazpryruvoyl Cross-Linking Agent for Bonding Tissue Containing Type-I Collagen.” Photochemistry and Photobiology. vol. 78, No. 1, 2003 (pp. 23-29).
Glenn J.V., et al., “Advanced Glycation End Product (AGE) Accumulation on Bruch's Membrane: Links to Age-Related RPE Dysfunction;” Investigative Ophthalmology & Visual Science, vol. 50, No. 1, pp. 441-451; Jan. 2009 (11 pages).
Gravitz L., “Laser Show in the Surgical Suite: Lasers and a century-old dye could supplant needles and thread;” technology review, MIT, Mar./Apr. 2009; retrieved from http://www.technologyreview.com/biomedicine/22088/?nlid=1767, on Sep. 26, 2011 (2 pages).
Hafezi F., et al., “Collagen Crosslinking with Ultraviolet-A and Hypoosmolar Riboflavin Solution in Thin Corneas,” J. Catract Refract. Surg., vol. 35, No. 1, pp. 621-624; Apr. 2009 (4 pages).
Hitzenberger et al., “Birefringence Properties Of The Human Cornea Measured With Polarization Sensitive Optical Coherence Tomography,” Bull. Soc. Beige Ophtalmol., 302, 153-168, 2006 (16 pages).
Holmström, B. et al., “Riboflavin As An Electron Donor In Photochemical Reactions,” 1867-1871, Nov. 29, 1960 (5 pages).
How to Use DEFINITY: “Frequently Asked Questions;” retrieved from http://www.definityimaging.com/how-faq.html, on Sep. 26, 2011 (3 pages) (date unknown, prior to Apr. 26, 2010).
IMEX, “KXL System: Crosslinking Para Cirugia Corneal Bibliografia Cientifica,” Product Literature, Nov. 23, 2010 (24 pages).
Kamaev et al., “Photochemical Kinetics Of Corneal Cross-Linking With Riboflavin,” Investigative Ophthalmology & Visual Science, Apr. 2012, vol. 53, No. 4, pp. 2360-2367 (8 pages).
Kampik D. et al., “Influence of Corneal Collagen Crosslinking With Riboflavin and Ultraviolet-A Irradiation on Excimer Laser Surgery,” Investigative Opthalmology & Visual Science, vol. 51, No. 8, pp. 3929-3934; Aug. 2010 (6 pages).
Kissner Anja, et al., “Pharmacological Modification of the Epithelial Permeability by Benzalkonium Chloride in UVA/Riboflavin Corneal Collagen Cross-Linking,” Current Eye Research 35(8), pp. 715-721; Mar. 2010 (7 pages).
Koller T., et al., “Therapeutische Quervernetzung der Hornhaut mittels UVA and Riboflavin: Therapeutic Cross-Linking of the Cornea Using Riboflavin/UVA,” Klinische Monatsblätter für Augenheilkunde, vol. 224, No. 9, pp. 700-706; Sep. 2007 (7 pages).
Kornilovsky, I. M. “Novye neinvazivnye tekhnologii lazernoy modifikatsii optiko-refraksionnykk struktur glaza. Refraktsionnaya khirurgiya I oftalmologiya.” vol. 9, No. 3, 2006 (pp. 17-26).
Krueger, Ronald R., “Rapid Vs Standard Collagen Cxl with Equivalent Energy Dosing,” presentation slides; available at http://www.slideshare.net/logen/krueger-herekar-rapid-crosslinking (date unknown, prior to Nov. 9, 2009) (26 pages).
Massey, V., “Activation of Molecular Oxygen by Flavins and Flavoproteins,” The Journal of Biological Chemistry vol. 269, No. 36, Issue of Sep. 9, pp. 22459-22462, 1994 (4 pages).
Li, C. et al. “Elastic Properties of Soft Tissue-Mimicking Phantoms Assessed by Combined Use of Laser Ultrasonics and Low Coherence Interferometry.” Optics Express. vol. 19, No. 11, May 9, 2011 (pp. 10153-10163).
Li, C. et al. “Noncontact All-Optical Measurement of Corneal Elasticity.” Optics Letters. vol. 37, No. 10, May 15, 2012 (pp. 1625-1627).
Li, P. et al. “In Vivo Microstructural and Microvascular Imaging of the Human Corneo-Scleral Limbus Using Optical Coherence Tomography.” Biomedical Optics Express. vol. 2, No. 11, Oct. 18, 2011 (pp. 3109-3118).
Mi S., et al., “The adhesion of LASIK-like flaps in the cornea: effects of cross-linking, stromal fibroblasts and cytokine treatment,” presented at British Society for Matrix Biology annual Meeting, Cardiff, UK, Sep. 8-9, 2008 (17 pages).
Muller L., et al., “The Specific Architecture of the Anterior Stroma Accounts for Maintenance of Corneal Curvature,” Br. J. Opthalmol., vol. 85, pp. 437-443; Apr. 2001 (8 pages).
Mulroy L., et al., “Photochemical Keratodesmos for repair of Lamellar corneal Incisions;” Investigative Ophthalmology & Visual Science, vol. 41, No. 11, pp. 3335-3340; Oct. 2000 (6 pages).
Naoumidi T., et al., “Two-Year Follow-up of Conductive Keratoplasty for the Treatment of Hyperopic Astigmatism,” J. Cataract Refract. Surg., vol. 32(5), pp. 732-741; May 2006 (10 pages).
O'Neil A.C., et al., “Microvascular Anastomosis Using a Photochemical Tissue Bonding Technique;” Lasers in Surgery and Medicine, vol. 39, Issue 9, pp. 716-722; Oct. 2007 (7 pages).
Paddock C., Medical News Today: “Metastatic Melanoma PV-10 Trial Results Encouraging Says Drug Company;” Jun. 9, 2009; retrieved from http://www.medicalnewstoday.com/articles/153024.php, on Sep. 26, 2011 (2 pages).
Pallikaris I., et al., “Long-term Results of Conductive Keratoplasty for low to Moderate Hyperopia,” J. Cataract Refract. Surg., vol. 31(8), pp. 1520-1529; Aug. 2005 (10 pages).
Pinelli, R. “Corneal Cross-Linking with Riboflavin: Entering a New Era in Ophthalmology.” Ophthalmology Times Europe. vol. 2, No. 7, Sep. 1, 2006, [online], [retrieved on May 20, 2013]. Retrieved from the Internet: <URL:http://www.oteurope.com/ophthalmologytimeseurope/Cornea/Corneal-cross-linking-with-riboflavin-entering-a-n/ArticleStandard/Article/detail/368411> (3 pages).
Pinelli R., et al., “C3-Riboflaving Treatments: Where Did We Come From? Where Are We Now?” Cataract & Refractive Surgery Today Europe, Summer 2007, pp. 36-46; Jun. 2007 (10 pages).
Ponce C., et al., “Central and Peripheral Corneal Thickness Measured with Optical Coherence Tomography, Scheimpflug Imaging, and Ultrasound Pachymetry in Normal, Keratoconus-suspect and Post-laser in situ Keratomileusis Eyes,” J. Cataract Refract. Surgery, vol. 35, No. 6, pp. 1055-1062; Jun. 2009 (8 pages).
Proano C.E., et al., “Photochemical Keratodesmos for Bonding Corneal Incisions;” Investigative Ophthalmology & Visual Science, vol. 45, No. 7, pp. 2177-2181; Jul. 2004 (5 pages).
Reinstein, D. Z. et al. “Epithelial Thickness Profile as a Method to Evaluate the Effectiveness of Collagen Cross-Linking Treatment After Corneal Ectasis.” Journal of Refractive Surgery. vol. 27, No. 5, May 2011 (pp. 356-363). [Abstract only].
Rocha K., et al., “Comparative Study of Riboflavin-Uva Cross-linking and “Flash-linking” Using Surface Wave Elastometry,” Journal of Refractive Surgery, vol. 24 Issue 7, pp. S748-S751; Sep. 2008 (4 pages).
Rolandi et al. Correlation of Collagen-Linked Fluorescence and Tendon Fiber Breaking Time. Gerontology 1991;27:240-243 (4 pages).
RxList: “Definity Drug Description;” The Internet Drug Index, revised Jun. 16, 2008, retrieved from http://www.rxlist.com/definity-drug.htm, on Sep. 26, 2011 (4 pages).
Sheehan M., et al., “Illumination System for Corneal Collagen Crosslinking,” Optometry and Vision Science, vol. 88, No. 4, pp. 512-524; Apr. 2011 (13 pages).
Shell, J., “Pharmacokinetics of Topically Applied Ophthalmic Drugs,” Survey of Ophthalmology, vol. 26, No. 4, pp. 207-218; Jan.-Feb. 1982 (12 pages).
Song P., Metzler D. Photochemical Degradation of Flavins—IV. Studies of the Anaerobic Photolysis of Riboflavin. Photochemistry and Photobiology, vol. 6, pp. 691-709, 1967 (21 pages).
Sonoda S., “Gene Transfer to Corneal Epithelium and Keratocytes Mediated by Ultrasound with Microbubbles,” Investigative Ophthalmology & Visual Science, vol. 47, No. 2, pp. 558-564; Feb. 2006 (7 pages).
Spoerl E., et al., “Artificial Stiffening of the Cornea by Induction of Intrastromal Cross-links,” Der Ophthalmologe, vol. 94, No. 12, pp. 902-906; Dec. 1997 (5 pages).
Spoerl E., et al., “Induction of Cross-links in Corneal Tissue,” Experimental Eye Research, vol. 66, Issue 1, pp. 97-103; Jan. 1998 (7 pages).
Spoerl E. et al., “Safety of UVA-Riboflavin Cross-Linking of the Cornea,” Cornea, vol. 26, No. 4, pp. 385-389; May 2007 (5 pages).
Spoerl E., et al., “Techniques for Stiffening the Cornea,” Journal of Refractive Surgery, vol. 15, Issue 6, pp. 711-713; Nov.-Dec. 1999 (4 pages).
Tessier Fj, et al., “Rigidification of Corneas Treated in vitro with Glyceraldehyde: Characterization of Two Novel Crosslinks and Two Chromophores,” Investigative Opthalmology & Visual Science, vol. 43, E-Abstract; 2002 (2 pages).
Trembly et al., “Microwave Thermal Keratoplasty for Myopia: Keratoscopic Evaluation in Porcine Eyes,” Journal of Refractive Surgery, vol. 17, No. 6, pp. 682-688; Nov./Dec. 2001 (8 pages).
“Uv-X: Radiation System for Treatment of Keratokonus,” PESCHKE Meditrade GmbH; retrieved from http://www.peschkemed.ch/ on Sep. 27, 2011 (date unknown, prior to Sep. 16, 2008) (1 page).
Vasan S., et al., “An agent cleaving glucose-derived protein crosslinks in vitro and in vivo;” Letters to Nature, vol. 382, pp. 275-278; Jul. 18, 1996 (4 pages).
Verzijl et al. Crosslinking by Advanced Glycation End Products Increases the Stiffness of the Collagen Network in Human Articular Cartilage. Arthritis & Rheumatism vol. 46, No. 1, Jan. 2002, pp. 114-123 (10 pages).
Wollensak G., et al., “Biomechanical and Histological Changes After Corneal Crosslinking With and Without Epithelial Debridement,” J. Cataract Refract. Surg., vol. 35, Issue 3, pp. 540-546; Mar. 2009 (7 pages).
Wollensak G., et al., “Collagen Crosslinking of Human and Porcine Sclera,” J. Cataract Refract. Surg., vol. 30, Issue 3, pp. 689-695; Mar. 2004 (7 pages).
Wollensak G., et al., “Cross-linking of Scleral Collagen in the Rabbit Using Riboflavin and UVA,” Acta Ophtalmologica Scandinavica, vol. 83(4), pp. 477-482; Aug. 2005 (6 pages).
Wollensak G., “Crosslinking Treatment of Progressive Keratoconus: New Hope,” Current Opinion in Ophthalmology, vol. 17(4), pp. 356-360; Aug. 2006 (5 pages).
Wollensak G., et al., “Hydration Behavior of Porcine Cornea Crosslinked with Riboflavin and Ultraviolet,” A.J. Cataract Refract. Surg., vol. 33, Issue 3, pp. 516-521; Mar. 2007 (6 pages).
Wollensak G., et al., “Riboflavin/Ultraviolet-A-induced Collagen Crosslinking for the Treatment of Keratoconus,” American Journal of Ophthalmology, vol. 135, No. 5, pp. 620-627; May 2003 (8 pages).
Wollensak, G. et al. “Laboratory Science: Stress-Strain Measurements of Human and Porcine Corneas after Riboflavin-Ultraviolet-A-Induced Cross-Linking.” Journal of Cataract and Refractive Surgery. vol. 29, No. 9, Sep. 2003 (pp. 1780-1785).
Yang H., et al., “3-D Histomorphometry of the Normal and Early Glaucomatous Monkey Optic Nerve Head: Lamina Cribrosa and Peripapillary Scleral Position and Thickness,” Investigative Ophthalmology & Visual Science, vol. 48, No. 10, pp. 4597-4607; Oct. 2007 (11 pages).
Yang N., Oster G. Dye-sensitized photopolymerization in the presence of reversible oxygen carriers. J. Phys. Chem. 74, 856-860 (1970) (5 pages).
Zang, Y. et al., “Effects of Ultraviolet-A and Riboflavin on the Interaction of Collagen and Proteoglycans during Corneal Cross-linking”, Journal of Biological Chemistry, vol. 286, No. 15, dated Apr. 15, 2011 (pp. 13011-13022).
Zderic V., et al., “Drug Delivery Into the Eye With the Use of Ultrasound,” J. Ultrasound Med, vol. 23(10), pp. 1349-1359; Oct. 2004 (11 pages).
Zderic V., et al., “Ultrasound-enhanced Transcorneal Drug Delivery,” Cornea vol. 23, No. 8, pp. 804-811; Nov. 2004 (8 pages).
International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2010/053551, mailed Dec. 21, 2010 (13 pages).
International Search Report and Written Opinion mailed Jul. 18, 2013 which issued in Application No. PCT/US2013/032567 (6 pages).
Related Publications (1)
Number Date Country
20140024997 A1 Jan 2014 US
Provisional Applications (1)
Number Date Country
61253736 Oct 2009 US
Continuations (1)
Number Date Country
Parent 12909228 Oct 2010 US
Child 14035528 US